Mr. X is a patient in his 40s diagnosed with acral melanoma. After undergoing radical surgery following his diagnosis in 2015, his condition remained stable for nine years. Unfortunately, about a year ago, his disease recurred with metastases to both lungs. Despite receiving inguinal and pelvic lymph node dissection as well as third-line systemic therapy (including PD-1 antibody treatment and NRAS mutation-targeted therapy), the tumors extensively involved both lungs, the groin, the subcutaneous tissue of the right abdominal wall, and the bilateral erector spinae muscles, leading to severe pain and a significant decline in quality of life.
At present, there are still many clinical trials of new anti-cancer technologies in China seeking patients. Consultation on new drugs and technologies, you can contact Beijing South Region Oncology Hospital International Department.
Phone Number：4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
In early 2025, Mr. X participated in a clinical trial of TIL cell therapy (GC101) and completed the TIL cell infusion in early June. Although his tumor burden was heavy, with the largest lesion measuring 62 mm, six weeks after the infusion, his overall target lesions shrank by 31.9%, with the largest single lesion shrinking by nearly 40%. The overall treatment efficacy reached partial response (PR). More importantly, Mr. X did not experience any major adverse reactions after GC101 TIL therapy, only common immunotherapy-related side effects such as chills and fever, which quickly resolved with symptomatic treatment.
About GC101
GC101 is an autologous natural TIL TIL therapy developed leveraging Juncell Therapeutics’ proprietary DeepTIL® cell expansion platform. DeepTIL® enables TILs to be potent enough that no IL-2 combination will be required after infusion, and the intensity of pretreatment could be lower.
As the first TIL therapy which only needs low-intensity pre-treatment and no IL-2 injection in the world, GC101 has been validated for its clinical efficacy and safety which greatly improves the safety and accessibility of TIL therapy.
About Melanoma
In China, the mortality rate of melanoma is higher and the incidence rate is increasing year by year. Compared with European or American, there are significant differences in the characteristics of melanoma in Chinese: about 90% of melanoma originates in the skin among European and American. In Asian, about 50% of melanoma originates at the extremity and 20-30% in the mucous membrane. In contrast, melanoma of the extremity and mucosal type has a worse prognosis.
At present, there are still many clinical trials of new anti-cancer technologies in China seeking patients. Consultation on new drugs and technologies, you can contact Beijing South Region Oncology Hospital International Department.
Phone Number：4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Post time: Aug-07-2025